Pfizer's Lipitor Patent Upheld
Posted on: Monday, 19 December 2005, 09:00 CST
Pfizer Inc. has scored a legal victory against India's Ranbaxy Laboratories Ltd., pushing a global effort annul patent protections from Lipitor.
Generic drugmaker Ranbaxy, which makes a copycat Lipitor for the Subcontinent market, lost a U.S. legal case that sought to have Pfizer's patents on Lipitor's active ingredient, atorvastatin, declared invalid.
But a federal court in Delaware ruled Friday that Pfizer is entitled to a permanent injunction against Ranbaxy from selling its generic version of atorvastatin for six more years. Ranbaxy intends to appeal the decision.
The decision heartened Pfizer's leadership.
Today marks a major victory for medical innovators and the patients who depend on them for important new therapies, said Pfizer Chief Executive Officer Hank McKinnell. Together with the decision in October by the United Kingdom's High Court of Justice, we have now successfully defended our Lipitor patent rights in two important jurisdictions.
Source: United Press International
Related Articles
- Ruling Upholds Pfizer's Lipitor Patent
- Pfizer's Lipitor Beats Rival in Heart Attack Study
- Pfizer's Lipitor Found to Reduce Recurrent Stroke Risk
- Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New Analysis Shows
- Lawsuit Attacks Pfizer's Lipitor Marketing
- Study Shows Potential of Pfizer's Lipitor in MS
- Pfizer's Lipitor Improves Kidney Function
- FDA OKs Pfizer's Lipitor for use in diabetics
- New Data Analysis Shows Patients With Diabetes Taking Pfizer's Lipitor(R) Experienced Major Reductions in Heart Attack and Stroke
 |
 |
User Comments (0)
RSS Feeds